The cost of multiple drug resistance in Pseudomonas aeruginosa
Open Access
- 17 April 2009
- journal article
- Published by Oxford University Press (OUP) in Journal of Evolutionary Biology
- Vol. 22 (5), 997-1003
- https://doi.org/10.1111/j.1420-9101.2009.01712.x
Abstract
The spread of bacterial antibiotic resistance mutations is thought to be constrained by their pleiotropic fitness costs. Here we investigate the fitness costs of resistance in the context of the evolution of multiple drug resistance (MDR), by measuring the cost of acquiring streptomycin resistance mutations (StrepR) in independent strains of the bacterium Pseudomonas aeruginosa carrying different rifampicin resistance (RifR) mutations. In the absence of antibiotics, StrepR mutations are associated with similar fitness costs in different RifR genetic backgrounds. The cost of StrepR mutations is greater in a rifampicin-sensitive (RifS) background, directly demonstrating antagonistic epistasis between resistance mutations. In the presence of rifampicin, StrepR mutations have contrasting effects in different RifR backgrounds: StrepR mutations have no detectable costs in some RifR backgrounds and massive fitness costs in others. Our results clearly demonstrate the importance of epistasis and genotype-by-environment interactions for the evolution of MDR.Keywords
This publication has 25 references indexed in Scilit:
- Epistatic buffering of fitness loss in yeast double deletion strainsNature Genetics, 2007
- Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2007
- Cost of Gram-negative resistance*Critical Care Medicine, 2007
- Epistasis correlates to genomic complexityProceedings of the National Academy of Sciences, 2006
- The biological cost of mutational antibiotic resistance: any practical conclusions?Current Opinion in Microbiology, 2006
- The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosisScience, 2006
- Impact of an Infection Control Program in an Intensive Care Unit in FranceInfection Control & Hospital Epidemiology, 2006
- Aminoglycoside Resistance inPseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Evidence for Positive Epistasis in HIV-1Science, 2004
- EPISTASIS BETWEEN NEW MUTATIONS AND GENETIC BACKGROUND AND A TEST OF GENETIC CANALIZATIONEvolution, 2001